SLAMF-7 BBz CAR

SLAMF-7 BBz CAR is a second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7), also known as CS1 or CD319. The construct consists of an extracellular single-chain variable fragment (scFv) specific for SLAMF7, linked to a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling subunit. SLAMF7 is a surface glycoprotein highly expressed on malignant plasma cells in multiple myeloma, as well as on natural killer (NK) cells and some activated T cells. By redirecting T cells to recognize SLAMF7, this therapy facilitates the targeted destruction of myeloma cells. A significant challenge with SLAMF7-targeted CAR-T cells is fratricide (self-killing), as T cells can express the target; this is often addressed through gene editing to knock out endogenous SLAMF7 in the therapeutic T cells. In the context of current research, SLAMF-7 BBz CAR is frequently utilized as a standard benchmark for evaluating the efficacy of next-generation multispecific or hybrid receptor platforms.

Other names

SLAMF7-directed 4-1BB-zeta CAR-TSLAMF-7-directed 4-1BB-zeta CAR-TSLAMF 7-directed 4-1BB-zeta CAR-TCS1-directed CAR-TCS-1-directed CAR-TCS 1-directed CAR-TCD319-directed CAR-TCD-319-directed CAR-TCD 319-directed CAR-T